Related Experiment Video

Updated: May 25, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Significant beneficial effect of AT-1 receptor blockers (sartans) in stroke

Marwan S Al-Nimer1

  • 1Department of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq. alnimermarwan@ymail.com

Neurosciences (Riyadh, Saudi Arabia)
|January 17, 2012
PubMed

Insights

Angiotensin receptor blockers (sartans) offer stroke protection beyond blood pressure control. These drugs reduce inflammation, improve cognitive function, and promote new blood vessel growth for cerebroprotection.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Hypertension is a primary modifiable risk factor for stroke.
  • A strong, linear relationship exists between blood pressure and stroke mortality.
  • Angiotensin receptor blockers (sartans) are established antihypertensive agents.

Purpose of the Study:

  • To review the multifaceted benefits of sartans in stroke management.
  • To explore sartans' effects beyond blood pressure reduction.
  • To consolidate findings from experimental and clinical stroke studies.

Main Methods:

  • Review of experimental and clinical studies on sartans and stroke.
  • Analysis of sartans' pharmacological actions, including anti-inflammatory and angiogenic effects.
  • Evaluation of clinical safety and efficacy in acute stroke patients.

Main Results:

  • Sartans exhibit anti-inflammatory properties by reducing cytokine levels.
  • These anti-inflammatory effects mitigate cerebral injury and enhance cognitive function post-stroke.
  • Sartans promote neovascularization, offering long-term cerebroprotection and vascular repair.

Conclusions:

  • Sartans provide significant benefits in stroke management, independent of blood pressure control.
  • Their anti-inflammatory and angiogenic effects contribute to improved stroke outcomes.
  • Sartans are safe for hypertensive acute stroke patients, offering therapeutic advantages.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...